Cure My Disease

Don't miss your cure!

 Log in / Sign up

New antidote for popular blood thinner shows promise in early trial

NCT ID NCT03288454

Completed Disease control Sponsor: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This Phase 2 study tested a drug called ciraparantag in 60 healthy adults aged 50 to 75 who were taking the blood thinner apixaban. The goal was to see if ciraparantag could quickly and safely reverse apixaban's blood-thinning effects, measured by clotting time. Participants received either ciraparantag or a placebo, and researchers checked if clotting returned to normal within hours.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ciraparantag (also called PER977 or AMAG 977)
What this could lead to
If successful, this could lead to a fast-acting antidote for the blood thinner apixaban, helping reverse its effects in emergencies like bleeding or urgent surgery.
What could go wrong
This is an early Phase 2 trial in only 60 healthy volunteers, not patients. It may not work as well in real-world bleeding situations, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

  • Frontage Clinical Services Inc.

    Secaucus, New Jersey, 07094, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.